![{[setting('site_name')]}](https://projxnews.com/uploads/setting/16983847711140531930.webp)
Srivin Life Sciences has announced a significant investment in a new Active Pharmaceutical Ingredients (API) project located in Chinakaparthy, Nalgonda, Telangana. The project, with a capital outlay of ₹18 crores, is set to enhance the company's manufacturing capabilities and meet the growing demand for high-quality APIs in the pharmaceutical industry.
The state-of-the-art facility aims to produce 341 tonnes per annum (TPA) of various active pharmaceutical ingredients. This move is expected to bolster Srivin Life Sciences' position in the market by expanding its product portfolio and ensuring a steady supply of essential APIs for both domestic and international markets.
With this new venture, Srivin Life Sciences plans to leverage advanced technology and stringent quality control measures to maintain high standards of production. The company emphasizes its commitment to adhering to regulatory requirements and industry best practices to ensure the safety and efficacy of its products.
The strategic location of the plant in Nalgonda, Telangana, provides logistical advantages, enabling efficient distribution of products. This investment is also anticipated to create job opportunities in the region, contributing to local economic development and supporting the government's initiatives to boost the pharmaceutical sector in India.
News by Rahul Yelligetti
